G uy A. Rouleau, M.D., Ph.D., FRCP(C), OQ - Dr. Guy Rouleau is the Director of the Research Centre of the CHU Sainte-Justine. He is a tenured professor in the Department of Medicine at Université de Montréal. He is the creator and Director of the Centre for excellence in neuromics and director of the Réseau de Médecine Génétique Appliquée – FRSQ. He is the Chairholder of the Canada Research Chair in Genetics of the Nervous System. At McGill University he is an Adjunct Professor in the Department of Human Genetics and holds cross appointments in the Departments of Psychiatry, Biology, and Human Genetics. He has published more than 420 articles in peer-reviewed journals, as well as 35 review articles and book chapters. Dr. Rouleau received his MD (Magna Cum Laude) in 1980 from the University of Ottawa. He went on to pursue a PhD in Genetics at Harvard University which he completed in 1989. His post-graduate research was done in Neuroscience at the Montreal Neurological Institute as well as at Massachusetts General Hospital. His clinical work was done in Internal Medicine at the Montreal General Hospital, in Neurology (residency) at the Montreal Neurological Institute, and in Neurology (Research Fellow) at the Massachusetts General Hospital. He has received numerous awards, the most recent of which are the Prix d’excellence, from the Département de médecine, Université de Montréal, the Prix Henry-Friesen from the Royal College of Physicians and Surgeons of Canada / The Canadian Society for Clinical Investigation. Most recently he was made an Officer of the National Order of Québec. He sits on the editorial boards of Neurology of Disease, Canadian Journal of Neurological Sciences, Annal of Human Genetics, American Journal of Human Genetics, and performs ad hoc reviews for more than 12 journals. He is or was a member, among others, of the Scientific Advisory Board of Généthon, Evry France; of the Medical and Research Advisory Board of the National Ataxia Foundation; of Human Genome Organization; of the Scientific Advisory Board, Fondation Jean Dausset; of the Board of directors, Fondation des Jumelles Coudé; of the Board of directors, Ataxia of Charlevoix-Saguenay Foundation; of the Board of directors, Cole Foundation; of Scientific Advisory Board of the Centre for Applied Genomics, Hospital for Sick Children; of the Science Advisory Council (SAC), Neuroscience Canada; of the Canadian Academy of Health Sciences and of the Science, Technology and Innovation Council, Government of Canada. He has also served on numerous grant panel committees (ex. CIHR, NIH, ALSA, NNFF, FRSQ) and Company Boards (Xenon Genetics Inc, Emerillon Therapeutics Inc, Biocapital Inc.). He has supervised many students (12 Master’s, 32 PhD, and 32 post-doctoral fellows). He is a founder of RGS Genome Inc. (1998-2000), director of Xenon Genetics Research Inc. (2000-2003) and founder/director/president of Emerillon Therapeutics Inc (2003-2009).
Over the last 20 years his work has focused on understanding the genetic basis for diseases of the brain. Specifically he has mapped over 20 disease loci, significantly contributed to the identification of over 10 genes causing diseases as well as to a better understanding of the pathogenesis of numerous diseases. He works on numerous neurological and psychiatric diseases, including amyotrophic lateral sclerosis, stroke, familial aneurysms, cavernous angiomas, epilepsy, spinocerebellar ataxia, spastic paraplegia, autism, Tourette syndrome, restless legs syndrome, schizophrenia and bipolar disorder. His laboratory endeavours to understand the pathogenesis of amyotrophic lateral sclerosis, oculopharyngeal muscular dystrophy and CAG repeat disorders using cell and animal models.
|
|
